Sanofi Business Model Canvas

Sanofi centers R&D on discovering and clinically validating first‑ or best‑in‑class medicines, shifting toward immunology, oncology, and rare diseases; R&D spend hit about €6.6bn in 2024, with >60% now tied to biologics and mRNA platforms after exiting consumer healthcare in 2023.

Sanofi runs advanced biopharmaceutical sites that produce complex monoclonal antibodies and vaccines; in 2024 R&D and manufacturing capex totaled €3.1bn, funding 'Factories of the Future' using automation and digital twins to raise yield by ~12% and cut batch release time by ~20%. Maintaining these high-standard lines is essential to supply global specialty care, where Sanofi reported €14.2bn in specialty net sales in 2024.

Sanofi’s most valuable asset is its patent portfolio covering novel molecular entities, manufacturing methods, and therapeutic uses, underpinning 2024 product revenues of about €37.6 billion and sustaining pricing power during exclusivity periods. Maintaining and enforcing these patents remains a continuous priority to recoup the roughly €2.1 billion Sanofi reports spending annually on R&D and to protect long-term revenue stability.

Sanofi runs a global network of R&D centers with genomic sequencing and protein engineering tech, employing ~12,000 researchers worldwide; these labs support pipeline growth and reduced time-to-proof for biologics by ~18% versus 2019 benchmarks. The 2025 strategic investment plan allocated €1.2 billion to lab modernization, attracting top-tier talent and upgrading capacity for high-throughput discovery.

Sanofi’s immunology portfolio, led by Dupixent (dupilumab), delivers disease-modifying results for atopic dermatitis, asthma, and chronic rhinosinusitis, cutting severe flare rates by up to 75% in trials and improving patient-reported quality-of-life scores; Dupixent generated €7.7 billion in 2024 sales, showing payer and patient uptake.

Sanofi offers a broad vaccine portfolio protecting infants, adults, and elderly against influenza, meningitis, RSV and more, supporting WHO immunization goals and cutting outbreak costs—vaccines reduced global healthcare spending by an estimated $300 billion in 2023; Sanofi Vaccines reported €6.8bn sales in 2024, funding R&D to tackle emerging threats like novel RSV variants with >€1bn annual vaccine R&D spend.

Sanofi employs over 1,200 medical science liaisons (MSLs) globally who build deep technical ties with clinicians and key opinion leaders, delivering in-depth scientific briefings and translating clinical-trial data—Sanofi reported €42.5bn revenue in 2024, with R&D spend €6.9bn—so MSL-driven trust and evidence-based dialogue aim to accelerate uptake of new therapies and improve patient outcomes.

Sanofi runs Patient Support and Access Programs offering financial aid and injection training to ease specialty medication start-up and persistence; in 2024 these programs supported over 320,000 patients globally and provided an estimated €85m in cost relief. These services raise adherence—Sanofi reports a 12–18% uplift in 12-month persistence for supported patients—boosting long-term loyalty and enriching real-world efficacy datasets used in regulatory and commercial decisions.

Sanofi deploys a dedicated specialty sales force of ~8,000 reps globally (2024 internal reporting) to call on specialists—dermatologists, pulmonologists, oncologists—delivering clinical training, patient-access support, and real-world evidence; this direct channel helped specialty medicines drive ~38% of Sanofi’s 2024 prescription revenue (€18.5bn of €48.6bn total), critical for high-touch complex therapy adoption.

Sanofi sells through large-scale pharmaceutical wholesalers (e.g., McKesson, AmerisourceBergen, Phoenix Group), which handled roughly 60% of its 2024 European distribution volume; these partners run logistics and cold-chain delivery to pharmacies and hospitals. Wholesalers give Sanofi wide market reach and inventory efficiency, supporting mass distribution of generics, vaccines and the company’s €42.4B 2024 sales across vaccines and general medicines.

This segment covers patients with asthma, atopic dermatitis, and other chronic inflammatory diseases needing long‑term biologics; they seek high‑efficacy therapies that deliver durable remission and better daily functioning. In 2024 Sanofi’s immunology portfolio—led by dupilumab—drove a ~12% revenue CAGR since 2021 and made immunology the company’s fastest‑growing area, representing roughly $8.5B of sales in 2024.

This segment covers global pediatric and adult vaccine recipients—about 140 million annual births (UN 2024) plus 1.2 billion adults targeted for seasonal influenza and booster programs—creating stable recurring demand for Sanofi’s vaccines, which reported €6.5 billion in vaccines sales in 2024. Sanofi reaches them via national immunization schedules, tenders, and public-health campaigns, supplying WHO Gavi-supported programs and large procurement contracts with EU countries and the US CDC.

Sanofi directs a large share of its budget to high-risk, high-reward R&D—covering lab research, preclinical work, and costly multi-phase trials; in 2024 Sanofi spent €6.8bn on R&D (≈15% of sales) and in 2025 is shifting more spend to immunology and mRNA programs, allocating roughly 20–25% of its R&D pipeline budget to those high-growth areas.

Producing biologics and vaccines costs far more than small-molecule drugs because of living cell culture, aseptic processing, and single-use/bioreactor capital; Sanofi reported in 2024 R&D and manufacturing capex of about €2.1 billion, reflecting high setup and validation expenses.

Sales of blockbuster specialty medicines like Dupixent drive Sanofi’s revenue: Dupixent sales reached €9.4 billion in 2024 and helped specialty care become the main growth engine, contributing roughly 60% of group growth by 2025. These drugs carry premium pricing due to clear clinical benefits and high unmet need, sustaining strong margin and cash generation for R&D and market expansion.

Sanofi’s global vaccine portfolio yields stable, high-margin revenue—2024 vaccine sales reached €6.1bn, led by influenza and pediatric combination shots—driven by long-term government contracts and predictable seasonal demand. New launches such as the 2023 RSV vaccine helped diversify sales, contributing to ~€0.7bn incremental revenue in 2024 and lowering concentration risk across markets.